New FDA Approved Drug for Chorea

The Huntington Study Group (HSG) shared that the Phase 3 KINECT-HD study resulted in FDA approval of valbenazine for treatment of chorea in Huntington’s disease (HD). As a vesicular monoamine transporter 2 (VMAT2) inhibitor, valbenazine reduced chorea symptoms as early as two weeks after initial dose.

Read the full press release here:

Categories: Uncategorized